IPSS-independent prognostic value of plasma CXCL10, IL-7 and IL-6 levels in myelodysplastic syndromes

Leukemia

Volumn 26, Issue 4, 2012, Pages 693-699

  Pardanani, A ^a   Finke, C ^a   Lasho, T L ^a   Al Kali, A ^a   Begna, K H ^a   Hanson, C A ^a   Tefferi, A ^a  

^a MAYO CLINIC   (United States)

Author keywords

cytokines; interleukin; IP 10; MDS; prognosis

Indexed keywords

CYTOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 6; INTERLEUKIN 7;

ADULT; AGED; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMATOLOGIC MALIGNANCY; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; THROMBOCYTOPENIA;

EID: 84859632009     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.251     Document Type: Article

References (38)

1. Ansell SM, Maurer MJ, Ziesmer SC, Slager SL, Habermann TM, Link B et al. Pretreatment serum cytokines predict early disease relapse and a poor prognosis in diffuse large B-cell lymphoma (DLBCL) patients. Blood (ASH Annual Meeting Abstracts) 2010; 116: 436.
2. Tefferi A, Vaidya R, Caramazza D, Finke C, Lasho T, Pardanani A. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol 2011; 29: 1356-1363.
3. Pardanani A, Begna K, Finke C, Lasho T, Tefferi A. Circulating levels of MCP-1, sIL-2R, IL-15, and IL-8 predict anemia response to pomalidomide therapy in myelofibrosis. Am J Hematol 2011; 86: 343-345.
4. Olnes MJ, Sloand EM. Targeting immune dysregulation in myelodysplastic syndromes. JAMA 2011; 305: 814-819.
5. Warlick ED, Miller JS. Myelodysplastic syndromes: the role of the immune system in pathogenesis. Leuk Lymphoma 2011; e-pub ahead of print 12 June 2011.
6. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114: 937-951.
7. Tefferi A, Vardiman JW. Myelodysplastic syndromes. N Engl J Med 2009; 361: 1872-1885.
8. Lim ZY, Killick S, Germing U, Cavenagh J, Culligan D, Bacigalupo A et al. Low IPSS score and bone marrow hypocellularity in MDS patients predict hematological responses to antithymocyte globulin. Leukemia 2007; 21: 1436-1441. (Pubitemid 46965284)
9. Jonasova A, Neuwirtova R, Cermak J, Vozobulova V, Mocikova K, Siskova M et al. Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow. Br J Haematol 1998; 100: 304-309. (Pubitemid 28131061)
10. Sloand EM, Olnes MJ, Shenoy A, Weinstein B, Boss C, Loeliger K et al. Alemtuzumab treatment of intermediate-1 myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissions. J Clin Oncol 2010; 28: 5166-5173.
11. Sloand EM, Wu CO, Greenberg P, Young N, Barrett J. Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. J Clin Oncol 2008; 26: 2505-2511.
12. Anderson LA, Pfeiffer RM, Landgren O, Gadalla S, Berndt SI, Engels EA. Risks of myeloid malignancies in patients with autoimmune conditions. Br J Cancer 2009; 100: 822-828.
13. Kristinsson SY, Bjorkholm M, Hultcrantz M, Derolf AR, Landgren O, Goldin LR. Chronic immune stimulation might act as a trigger for the development of acute myeloid leukemia or myelodysplastic syndromes. J Clin Oncol 2011; 29: 2897-2903.
14. Molldrem JJ, Jiang YZ, Stetler-Stevenson M, Mavroudis D, Hensel N, Barrett AJ. Haematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFU-GM and alterations in T-cell receptor Vbeta profiles. Br J Haematol 1998; 102: 1314-1322. (Pubitemid 28435218)
15. Epperson DE, Nakamura R, Saunthararajah Y, Melenhorst J, Barrett AJ. Oligoclonal T cell expansion in myelodysplastic syndrome: evidence for an autoimmune process. Leuk Res 2001; 25: 1075-1083. (Pubitemid 33000488)
16. Kiladjian JJ, Bourgeois E, Lobe I, Braun T, Visentin G, Bourhis JH et al. Cytolytic function and survival of natural killer cells are severely altered in myelodysplastic syndromes. Leukemia 2006; 20: 463-470. (Pubitemid 43291745)
17. Epling-Burnette PK, Bai F, Painter JS, Rollison DE, Salih HR, Krusch M et al. Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors. Blood 2007; 109: 4816-4824. (Pubitemid 46827777)
18. Kordasti SY, Ingram W, Hayden J, Darling D, Barber L, Afzali B et al. CD4+CD25high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS). Blood 2007; 110: 847-850. (Pubitemid 47267420)
19. Kotsianidis I, Bouchliou I, Nakou E, Spanoudakis E, Margaritis D, Christophoridou AV et al. Kinetics, function and bone marrow trafficking of CD4+CD25+FOXP3+ regulatory T cells in myelodysplastic syndromes (MDS). Leukemia 2009; 23: 510-518.
20. Stasi R, Brunetti M, Bussa S, Conforti M, Martin LS, La Presa M et al. Serum levels of tumour necrosis factor-alpha predict response to recombinant human erythropoietin in patients with myelodysplastic syndrome. Clin Lab Haematol 1997; 19: 197-201. (Pubitemid 27431473)
21. Tsimberidou AM, Estey E, Wen S, Pierce S, Kantarjian H, Albitar M et al. The prognostic significance of cytokine levels in newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndromes. Cancer 2008; 113: 1605-1613.
22. Hsu HC, Lee YM, Tsai WH, Jiang ML, Ho CH, Ho CK et al. Circulating levels of thrombopoietic and inflammatory cytokines in patients with acute myeloblastic leukemia and myelodysplastic syndrome. Oncology 2002; 63: 64-69. (Pubitemid 34977939)
23. Wang XS, Shi Q, Williams LA, Cleeland CS, Mobley GM, Reuben JM et al. Serum interleukin-6 predicts the development of multiple symptoms at nadir of allogeneic hematopoietic stem cell transplantation. Cancer 2008; 113: 2102-2109.
24. Kondo A, Yamashita T, Tamura H, Zhao W, Tsuji T, Shimizu M et al. Interferon-gamma and tumor necrosis factor-alpha induce an immunoinhibitory molecule, B7-H1, via nuclear factor-kappaB activation in blasts in myelodysplastic syndromes. Blood 2010; 116: 1124-1131.
25. Raza A, Mundle S, Shetty V, Alvi S, Chopra H, Span L et al. A paradigm shift in myelodysplastic syndromes. Leukemia 1996; 10: 1648-1652. (Pubitemid 26333819)
26. Shetty V, Mundle S, Alvi S, Showel M, Broady-Robinson L, Dar S et al. Measurement of apoptosis, proliferation and three cytokines in 46 patients with myelodysplastic syndromes. Leuk Res 1996; 20: 891-900. (Pubitemid 27042322)
27. Kornblau SM, McCue D, Singh N, Chen W, Estrov Z, Coombes KR. Recurrent expression signatures of cytokines and chemokines are present and are independently prognostic in acute myelogenous leukemia and myelodysplasia. Blood 2010; 116: 4251-4261.
28. Feng X, Scheinberg P, Wu CO, Samsel L, Nunez O, Prince C et al. Cytokine signature profiles in acquired aplastic anemia and myelodysplastic syndromes. Haematologica 2011; 96: 602-606.
29. Greenberg PL. Risk factors and their relationship to prognosis in myelodysplastic syndromes. Leuk Res 1998; 22(Suppl 1): S3-S6.
30. Greenberg P, Tuechler H, Schanz J, Sole F, Bennett JM, Garcia-Manero G et al. Revised International Prognostic Scoring System (IPSS-R), developed by the International Prognostic Working Group for Prognosis in MDS. Leuk Res 2011; 35(Suppl 1): S6.
31. Garcia-Manero G, Shan J, Faderl S, Cortes J, Ravandi F, Borthakur G et al. A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia 2008; 22: 538-543. (Pubitemid 351386723)
32. Kantarjian H, O'Brien S, Ravandi F, Cortes J, Shan J, Bennett JM et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer 2008; 113: 1351-1361.
33. Malcovati L, Germing U, Kuendgen A, Della Porta MG, Pascutto C, Invernizzi R et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007; 25: 3503-3510. (Pubitemid 47315575)
34. Malcovati L, Porta MG, Pascutto C, Invernizzi R, Boni M, Travaglino E et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 2005; 23: 7594-7603. (Pubitemid 46291823)
35. Milne CD, Paige CJ. IL-7: a key regulator of B lymphopoiesis. Sem Immunol 2006; 18: 20-30. (Pubitemid 43238333)
36. Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta 2011; 1813: 878-888.
37. Lee EY, Lee ZH, Song YW. CXCL10 and autoimmune diseases. Autoimmun Rev 2009; 8: 379-383.
38. Kotla V, Goel S, Nischal S, Heuck C, Vivek K, Das B et al. Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol 2009; 2: 36.